TSGH

TSGH is a French financial holding company within Institut Mérieux and the long-standing reference shareholder of Transgene. It is healthcare-related through its ownership and investment activities rather than through direct drug discovery, clinical development, or commercialization of its own therapeutic pipeline. TSGH has also owned healthcare manufacturing and services assets, including ABL Europe prior to its sale to Oxford Biomedica. For biotech analysts, the company is best understood as a strategic life sciences holding vehicle tied to the Mérieux family ecosystem, with influence through ownership, financing, and governance of portfolio companies rather than through standalone operating R&D programs.